在经营发展回顾中，公司在"一产""二产""三产"均有布局。"一产"建立创新平台，构建驴皮国际供应 链；"二产"聚焦滋补健康赛道，推进产品战略、营销创新、科研升级等；"三产"以文化为引领，开展文 旅活动。未来，公司在各产业也有明确规划，如"一产"升级采购体系，"二产"打造品牌、加强研 发，"三产"优化康养体验。 在产品方面，公司将复方阿胶浆定位为战略核心产品，联合推出黄芪精扩充补气补血矩阵。新品数字营 销聚焦线上渠道，"皇家围场1619"以做强鹿品类为目标推进产品研发与产业整合。健康消费品业务 对"桃花姬"从品牌、产品、渠道、研发多方面重塑。 此外，公司对股份回购持审慎开放态度，短期内优先高比例现金分红。海外业务采取"立足香港，面向 东南亚"战略，加强原料进口与产品引进。公司还将在重点城市药店建立熬胶中心，加强售后宣传。目 前公司管理层稳定，重点围绕研发、业务、智能制造领域引进人才。 8月22日，东阿阿胶在济南举行业绩说明会，吸引了中金公司、中信证券等19家机构的券商分析师及广 大投资者参与。公司董事、总裁孙金妮，独立董事文光伟，董事、董事会秘书、副总裁、财务总监丁红 岩，证券事务代表、董事会办公室总经理付延等 ...

深耕国内毛驴养殖布局，强化全球原料资源把控力。加强科研体 系建设，落地与国内知名院校全方位合作，建立"1 院 3 中心"创新平 台；与部分"一带一路"国家，签订毛驴产业化发展项目合作备忘录， 构建全体系的驴皮国际供应链。 股票代码：000423 股票简称：东阿阿胶 东阿阿胶股份有限公司投资者关系活动记录表 编号：2025-05 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者 | □媒体采访 √业绩说明会 | | 关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | | 中金公司、中信证券、中信建投、浙商证券、国金证券、兴业证 | | 参与单位名称 | 券、东吴证券、开源证券、华泰证券、华福证券、国海证券、光大证 | | | 券、国投证券、以谦基金、子竹资本、行远自迩投资、才华资管、中 | | 及人员姓名 | 信保诚基金、麦星投资、国寿安保基金等券商分析师及广大投资者朋 | | 友 | | | 时间 | 2025 年 8 月 22 日 | | 地点 | 济南 | | | 董事、总裁 孙金妮 | | 上市公司 | 独立董事 文光伟 | | 接待人员姓 ...

中证报中证网讯(王珞)8月21日晚，东阿阿胶（000423）正式发布2025年半年度报告。报告数据显示， 公司在上半年展现出强劲的发展态势，各项关键指标均实现稳健增长，在市场竞争中进一步巩固了自身 优势地位。 财务指标全面向好经营质量显著提升 2025年上半年，东阿阿胶实现营业收入30.51亿元，同比增长11.02%；归属于上市公司股东的净利润达 到8.18亿元，同比增长10.74%；归属于上市公司股东的扣除非经常性损益的净利润为7.88亿元，同比增 长12.58%。公司经营活动产生的现金流量净额为9.65亿元，同比增长4.70%，其中第二季度经营活动产 生的现金流量净额高达12.70亿元，成功扭转了一季度季节性承压的局面。上半年基本每股收益为1.2698 元，同比增长10.52%。 截至6月末，公司资产负债率仅为19.17%，偿债风险极低，财务结构持续优化。在经营层面，公司持续 深化供应链数字化管理，优化产品结构，聚焦高毛利品类，并进一步推动驴皮库存去化，有效提升了产 能利用率水平。在财务方面，公司现金流指标显著改善，应收账款余额较一季度期末下降3.56亿，环比 下降65.86%，回款效率大幅提升，有力印证 ...

8月21日晚间，"滋补养生第一品牌"东阿阿胶（000423）发布2025年半年报，业绩整体稳健增长，经营 性现金流与一季度相比有明显改善。 具体来看，报告期内东阿阿胶实现营业收入30.51亿元，同比增长11.02%；归属于上市公司股东的净利 润8.18亿元，同比增长10.74%；归属于上市公司股东的扣除非经常性损益的净利润7.88亿元，同比增长 12.58%；经营活动产生的现金流量净额9.65亿元，同比增长4.70%。 作为一家中华老字号企业，东阿阿胶始创于1952年，1996年在深交所挂牌上市，2005年加入华润（集 团）有限公司。其主要从事阿胶和阿胶系列及其他中成药等产品的研发、生产和销售，是阿胶行业标准 制定的引领者，是滋补健康引领者和中药企业高质量发展的典范。 近些年，为进一步巩固行业地位、拓展增长空间，东阿阿胶持续推进内部改革与战略升级。公司 以"1238"战略为指引，深化推进胶类产业链"三产融合"协同发展，继续做强做优做大阿胶主业，精准拓 深基石业务，统筹拓展潜力产品，着力培育外延品种。其中，以"皇家围场1619"等品牌为代表的"第二 增长曲线"不断拓展滋补领域边界，为大健康行业的发展探索全新方向 ...

Group 1 - The stock price of Dong'e Ejiao is reported at 51.10 yuan, down by 0.17 yuan, a decrease of 0.33% from the previous trading day [1] - The trading volume for the day was 35,346 hands, with a transaction amount reaching 181 million yuan [1] - Dong'e Ejiao is part of the traditional Chinese medicine industry, focusing on the research, production, and sales of Ejiao and related products [1] Group 2 - Dong'e Ejiao ranks first in the cash dividend payout ratio according to the latest 2025 cash dividend list for listed companies [1] - The total cash dividends for A-share listed companies in 2024 are projected to be 2.4 trillion yuan, an increase of 9% compared to 2023 [1] - Among 4,445 A-share listed companies that have been listed for more than three years, 2,447 companies have consistently paid cash dividends over the past three years [1]

Core Viewpoint - The article highlights the efforts of Dong'e Ejiao Co., Ltd. in preserving traditional Chinese medicine practices while embracing innovation and technology to meet modern consumer demands [1][4]. Group 1: Traditional Craftsmanship and Innovation - Dong'e Ejiao's production techniques are recognized as a national-level intangible cultural heritage, reflecting nearly 3,000 years of history [3]. - The company integrates modern technology with traditional methods, such as the use of steam ball skin machines to enhance production efficiency [3]. - The introduction of a fully automated production line for traditional Chinese medicine oral liquids represents a significant advancement in standardizing production processes [3]. Group 2: Consumer Engagement and Technology - Dong'e Ejiao collaborates with Anhui University of Chinese Medicine to implement AI tongue diagnosis technology, allowing consumers to receive personalized health plans based on uploaded tongue images [4]. - As of June this year, the company has recorded over 520,000 online appointments for traditional gel preparation and more than 12,000 intelligent body assessments [4]. Group 3: Cultural Tourism and Experience - The old factory site has been transformed into a cultural experience hotel, contributing to the Dong'e Traditional Chinese Medicine Cultural Tourism Zone, which includes various attractions [5]. - The tourism area is expected to receive over 1.3 million visitors in 2024, providing immersive experiences that promote the cultural significance of Ejiao [5]. - Dong'e Ejiao emphasizes the synergy between promoting traditional Chinese medicine culture and business development, viewing it as both a responsibility and a mission [5].

Core Points - The new regulation mandates that from July 1, 2023, medical institutions must scan drug traceability codes before settling with medical insurance funds, enhancing drug safety [1] - By January 1, 2026, all medical institutions are required to fully collect and upload drug traceability codes, establishing a comprehensive tracking system for pharmaceuticals [1] - The traceability code acts as a unique electronic identity for each drug, ensuring that each box of medication has a single sales record, thus preventing counterfeit and swapped drugs [1] Industry Impact - The integration of drug traceability codes with medical insurance is significant for public drug safety, effectively combating issues like "returned drugs" and fraudulent transactions [2] - The traceability system allows for precise monitoring of high-priced drugs, ensuring they are used appropriately and reach the patients in need [2] - The National Medical Insurance Administration has already demonstrated the effectiveness of this system by investigating the traceability codes of specific drugs, thereby safeguarding both drug safety and insurance funds [2] Public Engagement - Consumers are encouraged to actively participate in ensuring their own drug safety by following six key practices when purchasing medications, including verifying the presence of traceability codes and scanning them for authenticity [3] - The promotion of drug traceability codes is essential, with the goal of making the scanning process a standard practice in every drug transaction [3] - Strengthening regulatory measures around drug traceability codes will help close potential loopholes and enhance public health protection [3]

Core Viewpoint - Dong'e Ejiao is revitalizing its brand and product offerings to attract younger consumers while preserving its traditional heritage [1][2][3][4] Group 1: Company Overview - Dong'e Ejiao is located in Dong'e County, Shandong Province, and is recognized as a national industrial heritage site [1] - The company has a history of 3000 years in traditional Chinese medicine, specifically in the production of Ejiao [1] Group 2: Product Innovation - The company has introduced new products like "Little Gold Bar" Ejiao powder for easy consumption, and has collaborated with brands like Nayuki Tea and Disney to create innovative offerings [3] - The introduction of AI tongue diagnosis technology aims to provide personalized health solutions for consumers [3] Group 3: Market Performance - In 2024, Dong'e Ejiao achieved a revenue of 5.921 billion yuan, representing a year-on-year growth of 25.57%, and a net profit of 1.557 billion yuan, up 35.29% [4] - The company has seen significant engagement through its online services, with over 520,000 online appointments for Ejiao preparation and 12,000 instances of intelligent body condition testing [4] Group 4: Cultural and Tourism Integration - The transformation of the old factory site into a cultural experience hotel and the establishment of a medical tourism area aims to enhance consumer engagement and attract over 1.3 million visitors in 2024 [2]

Core Insights - The company is transforming its traditional manufacturing processes through smart manufacturing and AI technology, enhancing efficiency and product quality [1][2] - Financial performance shows significant growth, with revenue increasing from 3.849 billion to 5.921 billion and net profit rising from 440 million to 1.557 billion from 2021 to 2024 [1] - The company is focusing on digital transformation of its supply chain, which has led to an increase in gross margin from 47.57% in 2019 to 72.42% in 2024 [2] Digital Transformation and Product Development - The company is implementing AI-driven quality control and IoT-based environmental monitoring to enhance manufacturing capabilities [2] - New product lines such as "Peach Blossom Princess" and "Dong'e Ejiao Little Gold Bar" are expanding market reach and catering to consumer preferences [2] - The company is targeting the male health market, developing products like Ejiao and Cistanche raw liquid to create a comprehensive product matrix [2][3] Future Strategy and R&D Focus - The company plans to integrate primary, secondary, and tertiary industries to enhance resource supply, product innovation, and cultural tourism [3] - Five key R&D areas have been identified: innovation in gelatin-based medicines, major variety cultivation, new drug development, health consumer product development, and leading the donkey industry [3] - Increased investment in R&D and the establishment of a high-standard innovation system are priorities to enhance core competitiveness [3]

Core Insights - Dong'e Ejiao is leveraging digital transformation and automation to enhance production efficiency and quality control [1][2][3] Group 1: Production Innovations - Dong'e Ejiao has replaced manual glass bottle inspections with automated light inspection machines, improving accuracy and reducing worker fatigue [1] - The company has developed a six-axis robot for bottle handling, reducing the number of operators needed from five to two, thus lowering labor intensity [1] Group 2: Digital Management Systems - A digital signage production warning system has been implemented to achieve digital and visual management of the production process [2] - The optimization of the production and sales collaboration platform in 2024 has led to a 30% increase in planning accuracy, with main product planning accuracy exceeding 90% [2] Group 3: Supply Chain and Resource Management - Dong'e Ejiao has established a smart supply chain system that utilizes AI to predict and manage raw material supply, ensuring timely delivery [3] - The company has integrated technology and industry innovation to create a comprehensive digital system covering research, production, supply, sales, and inventory [3]